ALEX Trial: Alectinib vs Crizotinib in ALK-Positive NSCLC

ALEX Trial: Alectinib vs Crizotinib in ALK-Positive NSCLC

User Photo
AnnualMeeting2017

3 years
1,185 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
H. Jack West, MD of Swedish Cancer Institute discusses the results of the ALEX trial for ALK+ non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract LBA9008: Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study
Up Next Autoplay